Loading…
Sublingual immunotherapy induces IL-10–producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation
Background The immunologic mechanisms underlying sublingual immunotherapy (SLIT) are still unclear, particularly the role of regulatory T cells. Objective We sought to characterize allergen-specific T-cell responses during successful birch pollen SLIT. Methods Proliferation of PBMCs and PBMCs deplet...
Saved in:
Published in: | Journal of allergy and clinical immunology 2007-09, Vol.120 (3), p.707-713 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background The immunologic mechanisms underlying sublingual immunotherapy (SLIT) are still unclear, particularly the role of regulatory T cells. Objective We sought to characterize allergen-specific T-cell responses during successful birch pollen SLIT. Methods Proliferation of PBMCs and PBMCs depleted of CD25+ cells obtained from 9 patients before, after 4 weeks, and after 52 weeks of SLIT was assessed in response to the major birch pollen allergen Bet v 1, the homologous apple allergen Mal d 1, or tetanus toxoid. Allergen-induced cytokine responses and FoxP3 expression of T cells were analyzed by using real-time PCR. The role of IL-10 for regulatory activity of T cells was investigated. Results After 4 weeks, higher frequencies of circulating CD4+ CD25+ T cells were detected together with increased FoxP3 and IL-10 and reduced IL-4 and IFN-γ mRNA expression levels compared with those before SLIT. Proliferation to all 3 antigens was markedly reduced but increased significantly after depletion of CD25+ cells or addition of anti–IL-10 antibodies. After 52 weeks, proliferation in response to Mal d 1 or tetanus toxoid returned to pre-SLIT levels, whereas Bet v 1–induced proliferation remained significantly suppressed and was enhanced by neither depletion of CD25+ cells nor addition of anti–IL-10 antibodies. In parallel, increased IFN-γ and reduced IL-4, IL-10, and FoxP3 mRNA expression was detected. Neither TGF-β levels nor cell-cell contact–mediated suppression of CD4+ CD25+ cells changed during the course of SLIT. Conclusion SLIT induces regulatory T-cell suppression through IL-10 during the early phase and specific nonreactivity and immune deviation of allergen-specific T cells during the later phase of therapy. Clinical implications SLIT induces immune mechanisms comparable with subcutaneous specific immunotherapy. |
---|---|
ISSN: | 0091-6749 1097-6825 |
DOI: | 10.1016/j.jaci.2007.06.013 |